The open-label multicentre trial is set to involve 54 paediatric patients treated with JR-142, compared with the company’s currently marketed growth hormone therapy Growject. Credit: Shutterstock / ...

China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

Zura Bio has initiated the Phase II TibuSURE trial to assess tibulizumab, in treating systemic sclerosis (SSc) in adult patients.

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.